Last reviewed · How we verify
atorvastatin 7 days
Atorvastatin, marketed by Radboud University Medical Center, is a well-established drug with a key composition patent expiring in 2028. The drug's primary strength lies in its strong market presence and long-standing use for its primary indication. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | atorvastatin 7 days |
|---|---|
| Also known as | lipitor |
| Sponsor | Radboud University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin (PHASE1)
- A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (PHASE1)
- A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants (PHASE1)
- Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy (EARLY_PHASE1)
- MicroRNA Activation of LOX-1 Mechanisms in Endometriosis (PHASE4)
- Genetic Testing and Motivational Counseling for FH (NA)
- Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement (NA)
- Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |